EP0597968A1 - Nouveaux antagonistes des leucotrienes-b 4?, leur procede de fabrication et leur utilisation comme medicaments - Google Patents

Nouveaux antagonistes des leucotrienes-b 4?, leur procede de fabrication et leur utilisation comme medicaments

Info

Publication number
EP0597968A1
EP0597968A1 EP92916905A EP92916905A EP0597968A1 EP 0597968 A1 EP0597968 A1 EP 0597968A1 EP 92916905 A EP92916905 A EP 92916905A EP 92916905 A EP92916905 A EP 92916905A EP 0597968 A1 EP0597968 A1 EP 0597968A1
Authority
EP
European Patent Office
Prior art keywords
formula
antagonists
leukotriene
alkyl
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92916905A
Other languages
German (de)
English (en)
Inventor
Werner Skuballa
Bernd Buchmann
Josef Heindl
Wolfgang Fröhlich
Roland Ekerdt
Claudia Giesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0597968A1 publication Critical patent/EP0597968A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Definitions

  • the invention relates to new leukotriene B 4 antagonists. Process for their preparation and their use as medicinal products.
  • Leukotriene B 4 (LTB 4 ) was discovered in 1979 by B. Samuelsson and co-workers as a metabolite of arachidonic acid. In the biosynthesis, the enzyme 5-lipoxygenase first forms the leukotriene A 4 as a central intermediate, which is then converted into the LTB 4 by a specific hydrolase.
  • leukotrienes can be found in the following work: a) B. Samuelsson et al., Prostaglandins 19, 645 (1980); 17, 785 (1979). b) CN Serhan et al., Prostaglandins 34, 201 (1987).
  • Leukotriene B 4 is summarized in some recent work: a) The
  • LTB is an important inflammation mediator for inflammatory diseases in which leukocytes migrate into the diseased tissue.
  • LTB 4 is known to cause leukocyte adhesion to the blood vessel wall.
  • LTB 4 is chemotactically active, ie it triggers a directed migration of leukocytes in the direction of a gradient increasing
  • Leukotrienes and especially LTB 4 are involved in skin diseases that are associated with inflammatory processes (increased vascular permeability and edema, cell infiltration), increased proliferation of skin cells and itching, such as eczema, erythema, psoriasis,
  • leukotrienes and LTB 4 are particularly useful for arthritis
  • LTB 4 chronic lung diseases (e.g. asthma), rhinitis and inflammatory bowel diseases.
  • Antagonists against LTB 4 itself or inhibitors of those enzymes that are involved in the synthesis of LTB 4 can be effective as specific remedies, especially against diseases associated with inflammation and allergic reactions.
  • the invention relates to leukotriene B 4 antagonists of the formula I,
  • Y is a hydrogen atom or the radical CO-A-COR with A in the meaning of an alkylene group with 1-6 C atoms in the chain or one
  • R 1 and R 2 are OH
  • X, R 1 and R 3 as C 1 -C 4 alkoxy group can mean: methoxy, ethoxy, n-propoxy, isoproxy, n-butoxy, sec-butoxy and tert-butoxy.
  • R 3 or as radical R 4 can be: methyl, ethyl, n-propyl-isopropyl, n-butyl, sec-butyl, tert-butyl.
  • alkylene group Y with 1-6 C atoms straight-chain or branched-chain saturated radicals are suitable, such as.
  • the radical (C 3 -C 6 ) cycloalkyl (for R 1 , R 2 , R 3 and R 4 ) can be:
  • radicals C 7 -C 12 aralkyl in the definitions of R 1 , R 2 , R 3 and R 4 represent the following groups: benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 1-methyl-3-phenylpropyl ,
  • Inorganic and organic bases are suitable for salt formation, as are known to the person skilled in the art for the formation of physiologically compatible salts.
  • Examples include alkali metal hydroxides such as sodium and potassium hydroxide, alkaline earth metal oxides such as calcium hydroxide, ammonia, amines such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine. Morphine, tris (hydroxymethyl) methylamine, etc.
  • the compounds of formula I are reacted with ⁇ -, ⁇ - or ⁇ -cyclodextrin.
  • the ⁇ -cyclodextrin clathrates are preferred.
  • the invention also relates to a process for the preparation of leukotriene B 4 antagonists of the formula I, characterized in that a compound of the formula II,
  • Y is as defined above and R 5 is OH or CO-CH 2 -COOR 6 , where R 6 is a C 1 -C 4 alkyl group, with a compound of formula III.
  • Formula I implemented with organic or inorganic bases or cyclodextrins.
  • the reduction of carbonyl group A is preferably carried out with
  • the saponification of the esters of the formula I is carried out by methods known to the person skilled in the art, such as, for example, using basic catalysts.
  • the 1-carboxy compounds are used, for example
  • Esterification with diazo hydrocarbons takes place e.g. B. in that a solution of the diazo hydrocarbon in an inert solvent, preferably in diethyl ether, with the 1-carboxy compound in the same or in another inert solvent, such as. B. methylene chloride mixed. After completion of the reaction in 1 to 30 minutes, this will be
  • Diazoalkanes are either known or can be prepared by known methods [Org. Reactions Vol. 8, pages 389-394 (1954)].
  • Represents -O-aryl group takes place according to the methods known to those skilled in the art.
  • the 1-carboxy compounds are reacted with the corresponding arylhydroxy compounds with dicyclohexylcarbodiimide in the presence of a suitable base, for example pyridine, DMAP, triethylamine, in an inert solvent.
  • a suitable base for example pyridine, DMAP, triethylamine
  • Suitable solvents are methylene chloride, ethylene chloride, chloroform, ethyl acetate, tetrahydrofuran, preferably chloroform.
  • the reaction is carried out at temperatures between -30 ° C and +50 ° C, preferably at 10 ° C.
  • the leukotriene B 4 antagonists of the formula I with R in the meaning of a COOH group can be converted into a salt with suitable amounts of the corresponding inorganic bases with neutralization.
  • a water-miscible solvent e.g. As alcohol or acetone, the solid inorganic salt.
  • the LTB 4 acid z. B. in a suitable solvent for example ethanol, acetone, diethyl ether,
  • the salt is usually obtained in solid form or is isolated in a conventional manner after evaporation of the solvent.
  • the amide group -C-NHR 4 is introduced by the methods known to the person skilled in the art.
  • reaction of the mixed anhydride with the alkali salt of the corresponding amine or with ammonia is carried out in an inert solvent or solvent mixture, such as, for example, tetrahydrofuran, dimethoxyethane, dimethylformamide, hexamethylphosphoric triamide, at temperatures between -30 ° C. and + 60 ° C., preferably at 0 ° C. up to 30 ° C.
  • an inert solvent or solvent mixture such as, for example, tetrahydrofuran, dimethoxyethane, dimethylformamide, hexamethylphosphoric triamide
  • the compounds of the general formula II which serve as the starting material can be prepared, for example, by using 3-oxy-2-carbomethoxy-thiophen (N. Fiesselmann et. Al., Chemical Reports 87, 841 (1954)) in a manner known per se with Tert. -butyldimethylsilyl chloride and silyated by subsequent reduction with diisobutylaluminium hydride in the primal alcohol of formula IV.
  • the compounds of formula I are anti-inflammatory and anti-allergic. Consequently, the new leukotriene B 4 derivatives of the formula I are valuable pharmaceutical active ingredients.
  • the compounds of the formula I are particularly suitable for topical application, since they have a dissociation between the desired topical activity and undesirable systemic side effects.
  • the pharmaceutical specialties are produced in the usual way by adding the active ingredients to the desired ones with suitable additives
  • Application form such as. For example: solutions, lotions, ointments, creams or plasters.
  • the active substance concentration depends on the form of administration.
  • an active ingredient concentration of 0.0001% to 1% is preferably used.
  • the new compounds, if appropriate in combination with the customary carriers and auxiliaries, are also well suited for the production of inhalants which are suitable for the treatment of allergy
  • Respiratory diseases such as bronchial asthma or rhinitis can be used.
  • the new leukotriene B 4 antagonists are also suitable in the form of capsules, tablets or dragees, which preferably contain 0.1 to 100 mg of active ingredient or are administered orally, or in the form of suspensions, which preferably contain 1-200 mg of active ingredient per dose unit contained and applied rectally also for the treatment of allergic diseases of the
  • Intestinal tract such as ulcerative colitis and granulomatous colitis.
  • the new leukotriene B 4 derivatives can also be used in combination, for example with
  • Lipoxygenase inhibitors Lipoxygenase inhibitors, cyclooxygenase inhibitors, prostacyclin agonists, prostaglandin agonists, thromboxane antagonists, leukotriene D 4 antagonists,
  • Leukotriene E 4 antagonists can be used.
  • leukotriene F 4 antagonists can be used.
  • phosphodiesterase inhibitors can be used.
  • calcium antagonists or PAF antagonists can be used.
  • IR 3600, 3450, 2960, 2935, 2860, 1605, 1555, 1395, 840, 826 cm -1 .
  • IR 2960, 2938, 1650, 1530, 1435, 1410, 830 cm -1 .
  • Tetrahydrofuran add 76 mg of anhydrous lithium chloride and stir for 10 minutes at 0 ° C.
  • a solution of 360 mg of the aldehyde prepared above in 2.2 ml of tetrahydrofuran is then added dropwise, the mixture is stirred at 0 ° C. for 3 hours and then neutralized with acetic acid. It is diluted with ether, washed twice with water, dried over sodium sulfate and evaporated in vacuo. The residue is purified by chromatography.
  • IR 2960, 1736, 1640, 1602, 1260 cm -1 .

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Il est décrit des antagonistes des leucotriènes-B4 ayant la formule (I) dans laquelle X désigne un alkoxy en C1-C4 ou un -S(O)p-(C1-C4)-alkyle, P est égal à 0, 1 ou 2, Y désigne un atome d'hydrogène ou le reste COACOR2 où A est un groupe alkylène de 1 à 6 atomes de carbone dans la chaîne ou un reste (a), (b) ou (c), R1 et R2 désignent le reste OH, -O-(C1-C4)-alkyle, -O-(C3-C6)-cycloalkyle, -O-(C7-C12)-aralkyle ou le reste NR3R4 où R3 et R4 désignent un hydrogène, un alkyle en C1-C4, un cycloalkyle en C3-C6, un aryle en C6-C10 ou un aralkyle en C7-C12, ainsi que leurs sels obtenus avec des bases physiologiquement tolérables et leurs cyclodextrine-clathrates, leur procédé de fabrication et leur utilisation comme médicaments.
EP92916905A 1991-08-15 1992-08-06 Nouveaux antagonistes des leucotrienes-b 4?, leur procede de fabrication et leur utilisation comme medicaments Withdrawn EP0597968A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4127193 1991-08-15
DE4127193A DE4127193A1 (de) 1991-08-15 1991-08-15 Neue leukotrien-b(pfeil abwaerts)4(pfeil abwaerts)-antagonisten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PCT/EP1992/001816 WO1993004056A1 (fr) 1991-08-15 1992-08-06 Nouveaux antagonistes des leucotrienes-b4, leur procede de fabrication et leur utilisation comme medicaments

Publications (1)

Publication Number Publication Date
EP0597968A1 true EP0597968A1 (fr) 1994-05-25

Family

ID=6438494

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92250203A Withdrawn EP0529749A1 (fr) 1991-08-15 1992-08-06 Antagonistes de leukotriene-B4, procédé de leur préparation et leur utilisation comme médicaments
EP92916905A Withdrawn EP0597968A1 (fr) 1991-08-15 1992-08-06 Nouveaux antagonistes des leucotrienes-b 4?, leur procede de fabrication et leur utilisation comme medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP92250203A Withdrawn EP0529749A1 (fr) 1991-08-15 1992-08-06 Antagonistes de leukotriene-B4, procédé de leur préparation et leur utilisation comme médicaments

Country Status (8)

Country Link
US (1) US5541202A (fr)
EP (2) EP0529749A1 (fr)
JP (1) JPH07502260A (fr)
AU (1) AU2409292A (fr)
CA (1) CA2114951A1 (fr)
DE (1) DE4127193A1 (fr)
HU (1) HUT66135A (fr)
WO (1) WO1993004056A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US7317967B2 (en) * 2001-12-31 2008-01-08 B. Braun Medical Inc. Apparatus and method for transferring data to a pharmaceutical compounding system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235064A (en) * 1987-01-12 1993-08-10 Eli Lilly And Company Leukotriene antagonists
US4992576A (en) * 1987-01-12 1991-02-12 Eli Lilly And Company Intermediates for leukotriene antagonists
CA1320490C (fr) * 1987-01-12 1993-07-20 Darrel M. Gapinski Agents antiinflammatoires
DE3873278T2 (de) * 1987-09-22 1993-02-25 Merck & Co Inc Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
US4999436A (en) * 1987-09-22 1991-03-12 Merck & Co., Inc. Aryl-substituted thiophene 3-ols, derivatives and analogs useful as lipoxgenase inhibitors
DE4028866A1 (de) * 1990-09-07 1992-03-12 Schering Ag Neue leukotrien-b(pfeil abwaerts)4(pfeil abwaerts)-antagonisten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9304056A1 *

Also Published As

Publication number Publication date
WO1993004056A1 (fr) 1993-03-04
HU9400417D0 (en) 1994-05-30
EP0529749A1 (fr) 1993-03-03
AU2409292A (en) 1993-03-16
CA2114951A1 (fr) 1993-03-04
US5541202A (en) 1996-07-30
HUT66135A (en) 1994-09-28
DE4127193A1 (de) 1993-02-18
JPH07502260A (ja) 1995-03-09

Similar Documents

Publication Publication Date Title
EP0656896B1 (fr) Nouveaux antagonistes des leucotrienes b4, leur procede de preparation et leur utilisation comme medicaments
EP0399633B1 (fr) Dérivés de leukotriène B4, procédé pour leur préparation et leur utilisation comme médicaments
EP0801061A2 (fr) Dérivés de leucotriène B4, procédé de fabrication desdits dérivés et leur utilisation comme médicaments
EP0549621B1 (fr) Nouveaux antagonistes des leucotrienes b4, leur procede de production et leur utilisation comme medicaments
EP0419610B1 (fr) Nouveaux derives de leucotriene b4, procede pour la preparation, et leur utilisation comme medicaments
EP0529022B1 (fr) Nouveaux derives de leucotrienes b 4?, leur procede de preparation et leur utilisation comme medicaments
WO1993004056A1 (fr) Nouveaux antagonistes des leucotrienes-b4, leur procede de fabrication et leur utilisation comme medicaments
EP0344096B1 (fr) Dérivés de la leukotriène-B4, leur procédé et application thérapeutique
EP0741686B1 (fr) Nouveaux derives des leucotrienes b4, leurs procedes de fabrication et leur utilisation comme medicaments
EP0614457B1 (fr) Derives de leucotrienes-b 4?, leur procede de preparation et medicaments
EP0416069B1 (fr) Nouveaux derives de leucotriene b 4 , procede pour leur preparation, et leur emploi comme medicaments
EP0741687B1 (fr) Nouveaux derives des leucotrienes b4, leurs procedes de fabrication et leur utilisation comme medicaments
EP0983235B1 (fr) Derives de leucotriene b4, en particulier antagonistes d'oximo-ltb4
DE4236540A1 (de) Neue Leukotrien-B¶4¶-Derivate, Verfahren zu ihrer H erstellung und ihre Verwendung als Arzneimittel
DE4139868A1 (de) Neue Leukotrien-B¶4¶-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19722853A1 (de) Leukotrien-B¶4¶-Antagonisten, insbesondere 3-Carba-Tetrahydronaphthalin-LTB¶4¶-Antagonisten
DE19602929A1 (de) Neue Leukotrien-B·4·-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19722846A1 (de) Leukotrien-B¶4¶-Derivate, insbesondere 7-Methylcyclohexyl-LTB¶4¶-Antagonisten
DE19722845A1 (de) Leukotrien-B¶4¶-Derivate, insbesondere Interphenylen-7-Methylcyclohexyl-LTB¶4¶-Antagonisten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960222

18D Application deemed to be withdrawn

Effective date: 19960904